Some Counterclaims Axed As Improperly Pleaded In Stem Cell Therapy Patent Row
LOS ANGELES — Partly granting a biotechnology firm’s motion to dismiss a rival’s counterclaims against it in a dispute over stem cell therapy patents, a California federal judge found that two...To view the full article, register now.
Already a subscriber? Click here to view full article